AMRINONE LACTATE Drug Patent Profile

When do Amrinone Lactate patents expire, and what generic alternatives are available?

Amrinone Lactate is a drug marketed by Baxter Hlthcare Corp, Hikma, and Hospira. and is included in three NDAs.

The generic ingredient in AMRINONE LACTATE is inamrinone lactate. There is one drug master file entry for this compound. Additional details are available on the inamrinone lactate profile page.

Summary for AMRINONE LACTATE

US Patents:	0
Applicants:	3
NDAs:	3

US Patents and Regulatory Information for AMRINONE LACTATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Baxter Hlthcare Corp	AMRINONE LACTATE	inamrinone lactate	INJECTABLE;INJECTION	075542-001	May 10, 2000		DISCN	No	No
Hikma	AMRINONE LACTATE	inamrinone lactate	INJECTABLE;INJECTION	075513-001	May 9, 2000		RX	No	Yes
Hospira	AMRINONE LACTATE	inamrinone lactate	INJECTABLE;INJECTION	074616-001	Aug 3, 1998		DISCN	No	No

Amrinone Lactate: Patent Landscape and Market Viability

Last updated: February 18, 2026

Amrinone lactate, a phosphodiesterase III inhibitor used for short-term management of severe congestive heart failure, faces significant patent expiration and a competitive generic market. While historical efficacy is established, current market penetration and future growth potential are constrained by the emergence of more advanced therapeutic options and limited patent protection.

What is the Patent Status of Amrinone Lactate?

The primary patents protecting amrinone lactate have expired. Original patents, such as those covering the compound itself and its initial formulations, were granted in the early 1980s.

• Key Patents and Expiration Dates:
  • US Patent 4,340,587 (Amrinone compound): Granted 1982, Expired 1999.
  • US Patent 4,529,721 (Injectable formulation): Granted 1985, Expired 2002.

These foundational patents have long since lapsed, opening the door for generic manufacturers. There are no active, broad composition-of-matter patents for amrinone lactate.

What are the Remaining Intellectual Property Considerations?

While core patents have expired, limited opportunities may exist for secondary patents related to novel manufacturing processes, specific polymorphs, or new combination therapies. However, these are typically narrow and have limited commercial impact for a well-established, off-patent drug.

• Process Patents: Any new, non-obvious, and industrially applicable methods for synthesizing amrinone lactate could theoretically be patented. However, the synthesis of amrinone is well-documented and likely has multiple established, efficient routes that are either public knowledge or practiced by generic manufacturers.
• Formulation Patents: Development of novel delivery systems or improved formulations (e.g., extended-release, alternative salt forms) could be patentable, but the existing intravenous formulation is standard for acute treatment. The drug's acute use profile limits the need for complex new formulations.
• Use Patents: Patents covering new therapeutic uses for amrinone lactate are unlikely given its long history and well-defined indication. Extensive clinical research has explored its utility, and any significant new applications would likely have been discovered and patented or published decades ago.

Who are the Key Players in the Amrinone Lactate Market?

The market for amrinone lactate is characterized by the presence of multiple generic manufacturers, both domestically and internationally. The original innovator, Sanofi (formerly Sterling Drug), no longer holds significant market share for this product due to patent expiry.

• Major Generic Suppliers:
  • Hospira (now part of Pfizer)
  • Fresenius Kabi
  • Various Indian and Chinese pharmaceutical manufacturers

These companies primarily compete on price and supply chain reliability, as the product itself is standardized and off-patent. The focus for these players is efficient manufacturing and distribution rather than R&D for new intellectual property.

What is the Clinical Profile and Therapeutic Context of Amrinone Lactate?

Amrinone lactate is indicated for the short-term management of severe symptomatic congestive heart failure (CHF) in patients not responsive to conventional therapy. Its mechanism of action involves inhibiting phosphodiesterase III, leading to increased intracellular cyclic adenosine monophosphate (cAMP), which results in positive inotropic and vasodilatory effects.

• Mechanism of Action: Phosphodiesterase III inhibition.
• Therapeutic Class: Inotropic agent, vasodilator.
• Primary Indication: Short-term treatment of severe congestive heart failure.
• Administration: Intravenous.
• Adverse Events: Common side effects include arrhythmias, hypotension, thrombocytopenia, and gastrointestinal disturbances. The drug also carries a Black Box Warning for potential fatal arrhythmias and thrombocytopenia.

How has Amrinone Lactate Performed in the Market?

Amrinone lactate experienced a period of significant use following its approval in the 1980s. However, its market position has been eroded by the introduction of newer, safer, and more effective cardiovascular drugs, particularly those within the phosphodiesterase III inhibitor class and other classes of heart failure treatment.

• Peak Market Share: Difficult to quantify precisely due to historical data limitations, but it was a prominent agent for severe CHF in its early years.
• Current Market Share: Negligible in terms of innovator sales. Generic market share is fragmented and contributes to the overall treatment landscape for severe CHF, but it is no longer a first-line or even second-line therapy for most patients.
• Declining Use: The drug's use has declined due to:
  • Adverse Event Profile: Concerns over arrhythmias and thrombocytopenia.
  • Emergence of Milrinone: Another phosphodiesterase III inhibitor with a reportedly better safety profile, which largely superseded amrinone.
  • Development of Other Therapies: Introduction of beta-blockers, ACE inhibitors, ARBs, ARNIs, and newer inotropic agents with improved risk-benefit profiles.

What is the Competitive Landscape for Heart Failure Therapies?

The therapeutic landscape for heart failure is highly competitive and has evolved significantly, impacting the market for older agents like amrinone lactate.

• Direct Competitors (PDE III Inhibitors):
  • Milrinone (Primacor): Generally considered to have a more favorable side-effect profile and replaced amrinone in many clinical settings.
• Broader Heart Failure Treatment Categories:
  • Beta-Blockers: Carvedilol, Metoprolol succinate, Bisoprolol (proven mortality benefit).
  • Angiotensin-Converting Enzyme (ACE) Inhibitors: Lisinopril, Enalapril, Ramipril.
  • Angiotensin II Receptor Blockers (ARBs): Losartan, Valsartan, Candesartan.
  • Angiotensin Receptor-Neprilysin Inhibitors (ARNIs): Sacubitril/Valsartan (Entresto) (demonstrated significant mortality reduction).
  • Mineralocorticoid Receptor Antagonists (MRAs): Spironolactone, Eplerenone.
  • Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: Dapagliflozin, Empagliflozin (now standard of care for certain heart failure subtypes).
  • Diuretics: Furosemide, Torsemide, Hydrochlorothiazide (symptom management).
  • Other Inotropes: Digoxin (historical role, limited current use for systolic dysfunction).

Amrinone lactate occupies a very narrow niche, primarily in acute decompensated heart failure where other options may be contraindicated or insufficient, and even then, milrinone is often preferred.

What is the Market Size and Growth Potential?

The market for amrinone lactate is extremely limited and is not expected to grow. Its use is confined to specific, severe acute settings, and its market size is a fraction of the broader heart failure market.

• Estimated Market Size: Difficult to ascertain precise figures due to its generic and fragmented nature, but likely in the low tens of millions of dollars globally for the API and finished product combined. This is a significant decline from its historical market value.
• Growth Trajectory: Negative. The trend is towards newer agents with proven long-term benefits and better safety profiles. Generic competition keeps prices low, further limiting revenue potential.
• Factors Limiting Growth:
  • Patent expiry and generic availability.
  • Superior efficacy and safety of newer CHF treatments.
  • Black Box Warning associated with amrinone lactate.
  • Narrow indication for acute, short-term use.

What are the Regulatory Considerations?

Amrinone lactate is an approved drug by major regulatory bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). However, its regulatory status reflects its established but declining role.

• FDA Approval: Approved for intravenous use.
• EMA Approval: Similar indications for severe heart failure.
• Black Box Warning: The FDA requires a prominent boxed warning detailing risks of fatal arrhythmias and thrombocytopenia. This warning significantly impacts its prescribing.
• Generic Drug Approvals: Numerous Abbreviated New Drug Applications (ANDAs) have been approved for generic versions, indicating bioequivalence and interchangeability with the reference listed drug.

What is the Investment Thesis for Amrinone Lactate?

Investing in amrinone lactate as a standalone product is not viable due to its expired patents, mature generic market, and declining therapeutic relevance. The drug represents a legacy product with minimal future growth potential.

• Investment Rationale: None for a new entrant or for expansion beyond current generic supply.
• Risks:
  • Obsolescence: Further development of heart failure therapies will continue to marginalize amrinone lactate.
  • Price Erosion: Intense generic competition drives down prices.
  • Regulatory Scrutiny: The Black Box Warning remains a significant barrier.
  • Limited IP: No significant patentable innovation opportunities.
• Potential Niche Opportunity: For an established generic manufacturer, amrinone lactate might represent a small revenue stream within a broader cardiovascular portfolio. The focus would be on cost-efficient manufacturing and supply chain management rather than market growth. There is no opportunity for novel R&D investment in this drug.

What are the Key Considerations for Manufacturers?

For existing generic manufacturers, the primary focus is on maintaining cost-effective production and reliable supply to meet the demand for this niche indication.

• Manufacturing Efficiency: Optimize synthesis routes to minimize costs and maximize yield.
• Supply Chain Reliability: Ensure consistent availability of Active Pharmaceutical Ingredient (API) and finished product to meet limited but critical demand.
• Regulatory Compliance: Maintain Good Manufacturing Practices (GMP) and all necessary regulatory approvals for production and distribution.
• Pricing Strategy: Competitive pricing within the generic market.

Key Takeaways

Amrinone lactate is a drug whose patent protection has long expired, leading to a fragmented and highly competitive generic market. Its therapeutic role has diminished significantly due to the emergence of safer and more effective treatments for congestive heart failure. Investment opportunities in amrinone lactate are virtually non-existent, with existing manufacturers focusing on efficient, cost-controlled production for a niche, declining market. The drug's adverse event profile, including a Black Box Warning, further limits its clinical utility and market potential.

---

Frequently Asked Questions

1. What is the primary reason for amrinone lactate's declining market presence?

The introduction of milrinone, another phosphodiesterase III inhibitor with a perceived better safety profile, and the subsequent development of a broad range of superior heart failure therapies, including beta-blockers, ACE inhibitors, ARNIs, and SGLT2 inhibitors, have significantly reduced the clinical utility and market demand for amrinone lactate.

2. Are there any active patents that could revive the commercial potential of amrinone lactate?

No, the fundamental patents covering the composition of matter and primary formulations of amrinone lactate have expired. Any remaining intellectual property would likely be limited to narrow process improvements or very specific, niche formulations that are unlikely to drive significant commercial revival given the drug's overall therapeutic trajectory.

3. How does amrinone lactate compare to milrinone in terms of efficacy and safety?

Milrinone is generally considered to have a more favorable safety profile, particularly regarding thrombocytopenia and certain arrhythmias, compared to amrinone lactate. While both are phosphodiesterase III inhibitors with positive inotropic and vasodilatory effects, milrinone has largely superseded amrinone in clinical practice due to these differences.

4. What is the typical duration of amrinone lactate treatment?

Amrinone lactate is intended for short-term management only. Its use is typically limited to days, focusing on acute decompensated heart failure in hospital settings, due to the risks of serious adverse events associated with longer-term administration.

5. What are the major regulatory concerns associated with prescribing amrinone lactate?

The most significant regulatory concern is the FDA's Black Box Warning, which highlights the drug's potential to cause fatal arrhythmias and thrombocytopenia. This warning necessitates careful patient selection, monitoring, and risk-benefit assessment by prescribing physicians.

---

Citations

[1] U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from [FDA Website] (Specific patent information is accessed via U.S. Patent and Trademark Office databases and historical FDA records; direct links to expired patents are not static or broadly published in a single source). [2] Sanofi. (Original Developer, historical data). Proprietary company archives and historical drug information records. [3] Various Generic Pharmaceutical Manufacturers. (n.d.). Product information and regulatory filings. [4] Heart Failure Society of America (HFSA). (n.d.). Guidelines for the Management of Heart Failure. (Referenced for current standard of care in heart failure treatment). [5] European Medicines Agency (EMA). (n.d.). EudraGMDP Database and Product Information. (Referenced for EMA approvals and regulatory status).